secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-12-31T23:59:59+00:00
Accession:  0001558370-24-016505
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix BioTherapeutics amends bylaws to raise special meeting threshold to 25% and remove written consent
--------------------------------------------------------------------------------

- Stockholders now need 25% beneficial ownership (up from 10%) to call a special meeting.
- Company secretary must set meeting date at least 30 days after request (was 10 days).
- Stockholders can no longer act by written consent in lieu of a meeting.
- Exclusive forum provisions added: Delaware Chancery Court for state claims, federal courts for Securities Act claims.
- Enhanced procedural and disclosure requirements for stockholder proposals and director nominations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024016505/0001558370-24-016505-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024016505/plx-20241227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016505

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer